Analyst Rating Update on Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX) : Zacks Investment Research ranks Mirati Therapeutics (MRTX) as 4, which is a Sell recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 2, which indicates as a Buy.

Mirati Therapeutics (MRTX) : Average target price received by Mirati Therapeutics (MRTX) is $22.83 with an expected standard deviation of $6.91. The most aggressive target on the stock is $32, whereas the most downbeat target is $14. 6 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy.


Mirati Therapeutics (NASDAQ:MRTX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.59 and $4.52 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.26. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.19, notching a gain of 12.34% for the day. The total traded volume was 1,055,355 . The stock had closed at $4.62 on the previous day.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.